131 related articles for article (PubMed ID: 25533875)
1. Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue.
Scaturro AL; De Caro V; Campisi G; Giannola LI
Drug Deliv; 2016 Sep; 23(7):2355-2362. PubMed ID: 25533875
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of levodopa methyl ester intranasal delivery systems.
Chun IK; Lee YH; Lee KE; Gwak HS
J Parkinsons Dis; 2011; 1(1):101-7. PubMed ID: 23939261
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
5. Levodopa delivery systems: advancements in delivery of the gold standard.
Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
[TBL] [Abstract][Full Text] [Related]
6. Novel formulations and modes of delivery of levodopa.
Poewe W; Antonini A
Mov Disord; 2015 Jan; 30(1):114-20. PubMed ID: 25476691
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
[TBL] [Abstract][Full Text] [Related]
8. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.
Di Stefano A; Sozio P; Iannitelli A; Marianecci C; Santucci E; Carafa M
J Drug Target; 2006 Nov; 14(9):652-61. PubMed ID: 17090401
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
Zhou T; Hider RC; Jenner P; Campbell B; Hobbs CJ; Rose S; Jairaj M; Tayarani-Binazir KA; Syme A
Eur J Med Chem; 2010 Sep; 45(9):4035-42. PubMed ID: 20646792
[TBL] [Abstract][Full Text] [Related]
10. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
[TBL] [Abstract][Full Text] [Related]
11. Phosphoramidate derivates as controlled-release prodrugs of l-Dopa.
Olatunji FP; Kesic BN; Choy CJ; Berkman CE
Bioorg Med Chem Lett; 2019 Sep; 29(18):2571-2574. PubMed ID: 31400939
[TBL] [Abstract][Full Text] [Related]
12. Designing prodrugs for the treatment of Parkinson's disease.
Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
[TBL] [Abstract][Full Text] [Related]
13. New prospective in treatment of Parkinson's disease: studies on permeation of ropinirole through buccal mucosa.
De Caro V; Giandalia G; Siragusa MG; Sutera FM; Giannola LI
Int J Pharm; 2012 Jun; 429(1-2):78-83. PubMed ID: 22465630
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.
Lee YH; Kim KH; Yoon IK; Lee KE; Chun IK; Rhie JY; Gwak HS
Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):237-42. PubMed ID: 24363125
[TBL] [Abstract][Full Text] [Related]
15. Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.
Sintov AC; Levy HV; Greenberg I
Pharm Res; 2017 Jul; 34(7):1459-1468. PubMed ID: 28405912
[TBL] [Abstract][Full Text] [Related]
16. Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.
Ravani L; Sarpietro MG; Esposito E; Di Stefano A; Sozio P; Calcagno M; Drechsler M; Contado C; Longo F; Giuffrida MC; Castelli F; Morari M; Cortesi R
Mater Sci Eng C Mater Biol Appl; 2015 Mar; 48():294-300. PubMed ID: 25579926
[TBL] [Abstract][Full Text] [Related]
17. New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies.
Giannola LI; Paderni C; De Caro V; Florena AM; Wolff A; Campisi G
Curr Pharm Des; 2010; 16(6):653-9. PubMed ID: 20388075
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study.
D'Aurizio E; Sozio P; Cerasa LS; Vacca M; Brunetti L; Orlando G; Chiavaroli A; Kok RJ; Hennink WE; Di Stefano A
Mol Pharm; 2011 Dec; 8(6):2408-15. PubMed ID: 22014118
[TBL] [Abstract][Full Text] [Related]
19. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
20. Advances in prodrug design for Parkinson's disease.
Cacciatore I; Ciulla M; Marinelli L; Eusepi P; Di Stefano A
Expert Opin Drug Discov; 2018 Apr; 13(4):295-305. PubMed ID: 29361853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
